ArticleRadiation oncology (London, England)2025
Patterns of failure analysis and the role of consolidative thoracic radiotherapy in extensive‑stage small‑cell lung cancer treated with first‑line chemoimmunotherapy.
Article in Radiation oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe efficacy of consolidative thoracic radiotherapy (cTRT) for extensive-stage small-cell lung cancer (ES-SCLC) remains controversial in the immunotherapy era, and the failure patterns in these patients require further exploration. This study aimed to investigate the failure pattern and the efficacy of cTRT in ES-SCLC patients treated with first-line chemoimmunotherapy.
methodsBrain metastases (BMs)-free ES-SCLC patients treated with first-line chemoimmunotherapy were included and divided into different groups based on whether they received cTRT or not. Failure patterns were recorded. Kaplan-Meier survival curves and log-rank tests were used to compare the survival outcomes between the groups. Additionally, the survival benefits of cTRT were further evaluated through univariable and multivariate analyses. Propensity score matching (PSM) was used to balance the baseline characteristics.
resultsA total of 100 eligible BMs-free ES-SCLC patients were enrolled, with 24 (24.0%) in the cTRT group and 76 (76.0%) in the no-cTRT group. Failure pattern analyses revealed that intrathoracic failure remained the primary failure pattern in chemoimmunotherapy-treated ES-SCLC. The addition of cTRT to chemoimmunotherapy reduced the risk of intrathoracic failure (from 60.0% to 29.4%), and both intrathoracic and intracranial progression were delayed by cTRT before and after PSM. Moreover, cTRT significantly improved the overall survival (OS) of ES-SCLC patients compared to no-cTRT (median OS: not reached vs. 14.1 months; HR = 0.40, 95% CI: 0.22–0.70, P = 0.01). Grade 3 pneumonitis was recorded in 9.7% and 3% of patients in the cTRT group and the no-cTRT group, respectively. No cases of grade 4 or 5 pneumonitis occurred.
conclusionsIn conclusion, this study characterized the failure patterns in BMs-free ES-SCLC patients treated with chemoimmunotherapy. cTRT significantly reduces intrathoracic and intracranial progression, and these benefits significantly translated into improved progression free survival and OS in chemoimmunotherapy-responsive ES-SCLC. These findings warrant the validation of prospective trials in the immunotherapy era.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.